Deudomperidone
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Deudomperidone
- Molecular weight
- 429.94
- Structure (SMILES)
These details could not be displayed.
- cin 102
- CIN-102
- deudomperidone
- Deudomperidone
- deudomperidone [INN]
- DEUDOMPERIDONE [USAN]
- deudomperidone inn
- deudomperidone usan
- CAS registry numbers
- 2121525-08-2
- ChEMBL ID
- CHEMBL4594380
- InChIKey
- FGXWKSZFVQUSTL-GYABSUSNSA-N
- PubChem compound IDs
- 153420471
- FDA ingredient codes (UNII)
- HN0VIB0W8W
- First in class
- No
- Orphan designation
- No
- Drug name stem
- deu-
Open Targets mechanisms
- Mechanism
- Dopamine D2 receptor antagonist
- Action type
- Antagonist
- Target
- D(2) dopamine receptor
Investigated indications
- Condition
- Gastroparesis
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000948
- Subject identifier
- D018589
- Condition identifier
- EFO_1000948
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006769
- Highest recorded phase
- 2
- Event
- akathisia
- Reports
- 31
- Reporting signal score
- 71.5927
- Event
- anal stenosis
- Reports
- 7
- Reporting signal score
- 27.1776
- Event
- apgar score low
- Reports
- 7
- Reporting signal score
- 19.0367
- Event
- aphthous ulcer
- Reports
- 14
- Reporting signal score
- 31.9257
- Event
- behaviour disorder
- Reports
- 9
- Reporting signal score
- 22.0079
- Event
- behcet's syndrome
- Reports
- 13
- Reporting signal score
- 45.9125
- Event
- bezoar
- Reports
- 7
- Reporting signal score
- 21.9058
- Event
- bradypnoea
- Reports
- 10
- Reporting signal score
- 25.7116
- Event
- bronchopulmonary aspergillosis allergic
- Reports
- 7
- Reporting signal score
- 26.9433
- Event
- cafe au lait spots
- Reports
- 7
- Reporting signal score
- 36.1883
- Event
- cell death
- Reports
- 8
- Reporting signal score
- 19.9549
- Event
- cholestasis
- Reports
- 36
- Reporting signal score
- 63.252
- Event
- cognitive disorder
- Reports
- 26
- Reporting signal score
- 30.2685
- Event
- cogwheel rigidity
- Reports
- 7
- Reporting signal score
- 20.7367
- Event
- coma
- Reports
- 38
- Reporting signal score
- 50.1187
- Event
- condition aggravated
- Reports
- 70
- Reporting signal score
- 35.6044
- Event
- congenital anomaly
- Reports
- 20
- Reporting signal score
- 51.207
- Event
- cryptorchism
- Reports
- 7
- Reporting signal score
- 20.6185
- Event
- dacryostenosis acquired
- Reports
- 7
- Reporting signal score
- 24.8339
- Event
- dehydration
- Reports
- 62
- Reporting signal score
- 56.1766
- Event
- derealisation
- Reports
- 8
- Reporting signal score
- 25.6686
- Event
- dermatitis atopic
- Reports
- 10
- Reporting signal score
- 22.1479
- Event
- developmental hip dysplasia
- Reports
- 7
- Reporting signal score
- 23.072
- Event
- duodenal stenosis
- Reports
- 9
- Reporting signal score
- 36.8098
- Event
- dysphagia
- Reports
- 57
- Reporting signal score
- 63.5863
And 57 more, listed on the interactive page.
- NCT04026997
- NCT04208698
- NCT05832151
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 2
- Polar surface area
- 78.82
- Calculated partition coefficient (ALogP)
- 3.35
- Calculated partition coefficient (XLogP)
- 3.9
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 30
- Molecular formula
- C22H24ClN5O2
- Monoisotopic mass
- 429.1869597
- Natural product
- No
Related records
Trials (4)
- A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
- A Scintigraphy Study in Adults With Diabetic Gastroparesis
- A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.
- A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
In development for (1)
- Gastroparesis Phase 2